hit counter
Aptose Biosciences Inc. (APTO) Stock News Sentiment & Price - Sentifly
APTO - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Aptose Biosciences Inc. (APTO)

Canada
Biotechnology
NASDAQ
APTO Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
APTO Latest news
GlobeNewsWire
Neutral
Aptose Reports Results for the Third Quarter 2021
2021-11-11 16:01

- Conference call and webcast at 5:00 pm ET today -

GlobeNewsWire
Neutral
Aptose Clinical Data to be Presented at the 2021 ASH Annual Meeting
2021-11-04 09:00

HM43239 Data Accepted for Oral Presentation; Data for Luxeptinib and APTO-253 Accepted for Poster Presentation HM43239 Data Accepted for Oral Presentation; Data for Luxeptinib and APTO-253 Accepted for Poster Presentation

GlobeNewsWire
Neutral
Aptose Enters into Exclusive Worldwide License Agreement with Hanmi Pharmaceutical for Clinical-Stage Myeloid Kinome Inhibitor HM43239
2021-11-04 06:00

HM43239 delivers multiple complete responses (CRs) in diverse R/R AML patients

GlobeNewsWire
Neutral
Aptose to Report Third Quarter 2021 Financial Results and Hold Conference Call on Thursday, November 11, 2021
2021-10-26 07:30

SAN DIEGO and TORONTO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will report financial results for the quarter ended September 30, 2021, and provide a corporate update on Thursday, November 11, 2021, after the close of the market.

GlobeNewsWire
Neutral
Aptose Expands Senior Leadership Team
2021-10-25 08:00

Janet Clennett, CPA, appointed Vice President, Finance

GlobeNewsWire
Neutral
Aptose to Present at September Investor Conferences
2021-08-30 07:30

SAN DIEGO and TORONTO, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose management team will participate at the upcoming conferences in September 2021:

Zacks Investment Research
Positive
Aptose Biosciences (APTO) Moves to Buy: Rationale Behind the Upgrade
2021-08-06 13:49

Aptose Biosciences (APTO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

PennyStocks
Positive
5 Best Penny Stocks To Buy Right Now According To Insiders
2021-08-06 12:11

These Penny Stocks Have Insiders Excited To Buy Right Now. The post 5 Best Penny Stocks To Buy Right Now According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Zacks Investment Research
Negative
Aptose Biosciences (APTO) Loses 19.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
2021-08-06 11:30

Aptose Biosciences (APTO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Seeking Alpha
Positive
Aptose: High Risk, High Reward. Watch Its Phase I Studies
2021-08-05 18:25

Aptose's second quarter update was undramatic, with management indicating that they've fully enrolled their Phase I luxeptinib studies at 750mg and are moving on to 900mg. Dose escalation awaits in the APTO-253 AML/MDS study, but management is also going to start enrolling patients with certain eligible B-cell cancers.

Loading more news...